Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 25 November to Question 14520 on Compulsorily Detained Psychiatric Patients, how many people have been held in Section 136 suites for over 24 hours in the last five years; and under which section of the Mental Health Act 1983 they were held.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Department does not hold the information in the format requested. Information on the number of uses of section 136 suites, collected by NHS England, is available at the following link:
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether his Department plans to meet regularly with the Cambridgeshire and Peterborough Integrated Care Board; and whether he plans to issue guidance to the Board on the the construction of a town hub in Northstowe.
Answered by Karin Smyth - Minister of State (Department of Health and Social Care)
The Department currently has no plans to meet regularly with the Cambridgeshire and Peterborough Integrated Care Board, and is not taking any steps to issue guidance to the ICB on the construction of a town hub in Northstowe.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he plans to extend the extra funding awarded to early support hubs after March 2025.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
My Rt. Hon. Friend, the Chancellor of the Exchequer presented the Autumn Budget to Parliament on 30 October 2024. As a Department, we are finalising the outcomes of the Budget. We will set out plans for mental health funding for 2025/26 in due course. We remain committed to improving mental health support for children and young people, with our commitment to roll out a network of Young Futures Hubs to provide open access mental health support as proof of this.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, what progress he has made on ensuring that children and young people in every community have access to drop in mental health support.
Answered by Stephen Kinnock - Minister of State (Department of Health and Social Care)
The Government is committed to improving mental health support for children and young people. Our commitment to roll out a network of Young Futures Hubs in every community to provide open access mental health support is proof of this.
We are currently working across Government to consider options in order to deliver Young Futures Hubs. The hubs will bring together services, including mental health support, to improve how young people access opportunities and support at the community level.
Asked by: Ian Sollom (Liberal Democrat - St Neots and Mid Cambridgeshire)
Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, whether he has made an assessment of the potential merits of the updated 2024-2025 Nuvaxovid™ COVID-19 Vaccine.
Answered by Andrew Gwynne - Parliamentary Under-Secretary (Department of Health and Social Care)
All vaccines in the United Kingdom must be authorised by the Medicines and Healthcare products Regulatory Agency (MHRA) before they can be placed on the UK market. The MHRA assesses all applications for authorisations of vaccines promptly, to ensure their safety, quality, and efficacy.
The updated 2024-2025 Nuvaxovid COVID-19 Vaccine has not been authorised by the MHRA. We are unable to confirm whether the MHRA has or has not received an application for Novavax's updated 2024-2025 Nuvaxovid COVID-19 Vaccine, as this information is considered commercially sensitive.
Pharmaceutical companies can decide to make information regarding the status of their Marketing Authorisation Applications publicly available, and the MHRA advocates that companies publish information on medicines in their pipelines, where and when it is reasonable to do so.